(Adnkronos) - “Questo nuovo farmaco agisce come inibitore del sistema JAK/STAT ed è in grado di bloccare l'infiammazione della cute. È importantissimo poter disporre di questa nuova terapia che consentirà ai nostri pazienti affetti da eczema cronico delle mani di controllare tale patologia, di agire sulla sintomatologia soggettiva correlata (prurito, bruciore, dolore) determinando un netto miglioramento della loro qualità di vita, oltre che di apportare un tangibile beneficio sulle lesioni cutanee. Nei tre studi clinici di fase 3 condotti utilizzando delgocitinib per l'eczema cronico delle mani sono stati raggiunti tutti gli obiettivi. I risultati dei primi 2 studi (per una durata di 16 settimane di terapia) sono stati recentemente pubblicati su Lancet, mentre i risultati del terzo studio (per una durata di 52 settimane di terapia) sono in corso di pubblicazione.
Category
🗞
NewsTranscript
00:00What is the role of medicine in the treatment of chronic diseases?
00:04As in terms of medicine, it is always said that the first form of therapy is prevention.
00:10Therefore, it is very important, when prevention fails to act, to have available therapeutic presuppositions
00:17that allow these patients affected by the chronic disease of the hands to be able to optimize a therapy
00:25that allows to greatly improve the quality of life, as well as, clearly, to bring an absolutely tangible benefit
00:34on the same goals that characterize these pathologies located exclusively in the hands.
00:41Until recently, we had an extremely limited number of therapeutic approaches
00:48that, in light and moderate forms, consisted almost exclusively of the use of products for local use,
00:57for topical use, based on molecules and corticosteroids at medium-low power,
01:03also the use of high-power corticosteroids for atomic therapy in the most serious forms,
01:09the only drug for systemic administration that was approved, many years ago, for the chronic disease of the hands,
01:19a drug that, however, has a definitely challenging safety profile for the patient,
01:26engraved also by a series of events between which, certainly, the theratogenicity.
01:34Of course, the greater understanding of the pathogenic mechanisms of this clinical framework
01:40has led to a line of development of drugs that somehow block the inflammatory mechanism
01:50and all the modulations that are at the base of these inflammatory processes of the hands,
01:55and, in particular, a lot of attention has been paid to some categories of drugs
02:03that go with a mechanism that we call a jack start, that is, a mechanism of transduction of the inflammatory signal,
02:12to make significant contributions, and, in particular, one of these drugs
02:18that was recently, at the end of September, approved by the European Agency for its Clinical Use,
02:26I am referring to Delgocitinib.
02:29Delgocitinib is a molecule that will mark an important turning point in the treatment of patients affected by chronic hand enzymes,
02:39because it is a drug for topical use, therefore, vapourized in the form of a cream,
02:44which blocks many of the mechanisms that then lead to the production of these inflammatory molecules,
02:54which are directly responsible for the damage to the cutaneous level.
02:57Delgocitinib, being a jack start, acts on many mechanisms that then lead to the formation of these inflammatory cytokines
03:07on different aspects of our immunity.
03:09This is the reason why the drug, in Phase I and II studies,
03:15conducted in 16 weeks, but also in the longest study, in 32 weeks,
03:22and the results of Phase III studies in 16 weeks,
03:29which were recently published on Lancet,
03:32in fact, I am honored to be one of the authors of this article,
03:37have shown the achievement of all the endpoints that appeared among the primary objectives of the study.